| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 1.136 | 5.837 | 8.264 | 9.627 | 9.116 | 20.146 | 32.305 | 41.824 | 48.931 |
| Total Income - EUR | - | 1.136 | 5.837 | 8.264 | 11.491 | 9.116 | 20.595 | 32.795 | 42.315 | 49.418 |
| Total Expenses - EUR | - | 209 | 512 | 2.402 | 6.539 | 9.168 | 13.376 | 23.382 | 16.504 | 36.982 |
| Gross Profit/Loss - EUR | - | 927 | 5.325 | 5.861 | 4.952 | -51 | 7.219 | 9.414 | 25.810 | 12.436 |
| Net Profit/Loss - EUR | - | 892 | 5.150 | 5.613 | 4.663 | -312 | 6.627 | 8.712 | 25.455 | 11.188 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Angiolife Dr. Puscasu Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 1.864 | 2.022 | 2.918 | 3.617 | 6.918 | 38.495 |
| Current Assets | - | 971 | 6.126 | 11.634 | 14.261 | 15.433 | 20.526 | 28.487 | 49.888 | 28.887 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 849 | 0 | 0 |
| Receivables | - | 273 | 301 | 289 | 221 | 0 | 255 | 587 | 42.454 | 17.437 |
| Cash | - | 698 | 5.825 | 11.345 | 14.039 | 15.433 | 20.272 | 27.050 | 7.434 | 11.450 |
| Shareholders Funds | - | 937 | 6.071 | 11.573 | 16.012 | 15.397 | 21.682 | 30.461 | 55.824 | 66.699 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 34 | 54 | 60 | 112 | 57 | 255 | 621 | 453 | 643 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 2.001 | 1.508 | 1.022 | 530 | 40 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Angiolife Dr. Puscasu Srl